Monopar Therapeutics (MNPR) Cash & Equivalents: 2016-2020
Historic Cash & Equivalents for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to $18.0 million.
- Monopar Therapeutics' Cash & Equivalents rose 300.10% to $18.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $18.0 million, marking a year-over-year increase of 300.10%. This contributed to the annual value of $13.2 million for FY2019, which is 91.71% up from last year.
- As of Q3 2020, Monopar Therapeutics' Cash & Equivalents stood at $18.0 million, which was up 43.33% from $12.5 million recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Cash & Equivalents peaked at $18.0 million during Q3 2020, and registered a low of $2.9 million during Q4 2016.
- Its 3-year average for Cash & Equivalents is $9.4 million, with a median of $8.2 million in 2018.
- Per our database at Business Quant, Monopar Therapeutics' Cash & Equivalents tumbled by 41.00% in 2019 and then surged by 300.10% in 2020.
- Over the past 5 years, Monopar Therapeutics' Cash & Equivalents (Quarterly) stood at $2.9 million in 2016, then spiked by 240.48% to $9.8 million in 2017, then fell by 29.54% to $6.9 million in 2018, then soared by 91.71% to $13.2 million in 2019, then spiked by 300.10% to $18.0 million in 2020.
- Its last three reported values are $18.0 million in Q3 2020, $12.5 million for Q2 2020, and $12.6 million during Q1 2020.